Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refractory B-cell malignancies, but resistance and relapses still occur. Better understanding of mechanisms influencing CAR T-cell cytotoxicity and the potential for modulation using small-molecule drugs could improve current immunotherapies. Here, we systematically investigated druggable mechanisms of CAR T-cell cytotoxicity using >500 small-molecule drugs and genome-scale CRISPR-Cas9 loss-of-function screens. We identified several tyrosine kinase inhibitors that inhibit CAR T-cell cytotoxicity by impairing T-cell signaling transcriptional activity. In contrast, the apoptotic modulator drugs SMAC mimetics sensitized B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma cells to anti-CD19 CAR T cells. CRISPR screens identified death receptor signaling through FADD and TNFRSF10B (TRAIL-R2) as a key mediator of CAR T-cell cytotoxicity and elucidated the RIPK1-dependent mechanism of sensitization by SMAC mimetics. Death receptor expression varied across genetic subtypes of B-cell malignancies, suggesting a link between mechanisms of CAR T-cell cytotoxicity and cancer genetics. These results implicate death receptor signaling as an important mediator of cancer cell sensitivity to CAR T-cell cytotoxicity, with potential for pharmacological targeting to enhance cancer immunotherapy. The screening data provide a resource of immunomodulatory properties of cancer drugs and genetic mechanisms influencing CAR T-cell cytotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, CRISPR screening showed that loss of tumor-associated death receptors leads to CAR T-cell resistance.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
CRISPResso2 provides accurate and rapid genome editing sequence analysis
Clement, K., Rees, H., Canver, M. C., Gehrke, J. M., Farouni, R., Hsu, J. Y., Cole, M. A., Liu, D. R., Joung, J. K., Bauer, D. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0032-3 · Cited by 1,660
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Straus, D. (1992) · Cell · doi:10.1016/0092-8674(92)90428-f · Cited by 1,034
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Targeting IAP proteins for therapeutic intervention in cancer
Fulda, S., & Vucic, D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3627 · Cited by 837
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 749
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Gu, Z., Churchman, M. L., Roberts, K. G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K., Pelletier, S., Gingras, S., Berns, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0315-5 · Cited by 603
Jurkat T cells and development of the T-cell receptor signalling paradigm
Abraham, R. T., & Weiss, A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1330 · Cited by 598
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Regulatory mechanisms in T cell receptor signalling
Gaud, G., Lesourne, R., & Love, P. E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0020-8 · Cited by 532
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
LAT Is Required for TCR-Mediated Activation of PLCγ1 and the Ras Pathway
Finco, T. S., Kadlecek, T., Zhang, W., Samelson, L. E., & Weiss, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80659-7 · Cited by 495
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 429
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Frey, N., & Porter, D. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.756 · Cited by 399
(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393
Self-citationTumor immune evasion arises through loss of TNF sensitivity
Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381
Yadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) · Scientific Reports · doi:10.1038/srep05193 · Cited by 359
Self-citationShan, X., Czar, M. J., Bunnell, S. C., Liu, P., Liu, Y., Schwartzberg, P. L., & Wange, R. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.18.6945-6957.2000 · Cited by 350
Weiss, A., Koretzky, G., Schatzman, R. C., & Kadlecek, T. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5484 · Cited by 341
Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., et al. (2019) · Blood · doi:10.1182/blood.2019001463 · Cited by 286
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
DeSelm, C., Palomba, M. L., Yahalom, J., Hamieh, M., Eyquem, J., Rajasekhar, V. K., & Sadelain, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.008 · Cited by 273
Pharmacologic control of CAR-T cell function using dasatinib
Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 239
Infante, J. R., Dees, E. C., Olszanski, A. J., Dhuria, S. V., Sen, S., Cameron, S., & Cohen, R. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3993 · Cited by 210
Jutz, S., Leitner, J., Schmetterer, K., Doel-Perez, I., Majdic, O., Grabmeier-Pfistershammer, K., Paster, W., Huppa, J. B., & Steinberger, P. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.01.007 · Cited by 207
Self-citationFADD: a regulator of life and death
Tourneur, L., & Chiocchia, G. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.05.005 · Cited by 203
IAP antagonists induce anti-tumor immunity in multiple myeloma
Chesi, M., Mirza, N. N., Garbitt, V. M., Sharik, M. E., Dueck, A. C., Asmann, Y. W., Akhmetzyanova, I., Kosiorek, H. E., Calcinotto, A., Riggs, D. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4229 · Cited by 171
IAP inhibitors enhance co-stimulation to promote tumor immunity
Dougan, M., Dougan, S., Slisz, J., Firestone, B., Vanneman, M., Draganov, D., Goyal, G., Li, W., Neuberg, D., Blumberg, R., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101123 · Cited by 147
Beug, S. T., Beauregard, C. E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D. E., Mohan, A., Earl, N., Lun, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms14278 · Cited by 140
PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models
Astoul, E. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01973-1 · Cited by 135
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Amaravadi, R. K., Schilder, R. J., Martin, L. P., Levin, M., Graham, M. A., Weng, D. E., & Adjei, A. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0475 · Cited by 131
Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity
Ratzinger, F., Haslacher, H., Poeppl, W., Hoermann, G., Kovarik, J. J., Jutz, S., Steinberger, P., Burgmann, H., Pickl, W. F., & Schmetterer, K. G. (2014) · Scientific Reports · doi:10.1038/srep07438 · Cited by 122
Self-citationKaartinen, T., Luostarinen, A., Maliniemi, P., Keto, J., Arvas, M., Belt, H., Koponen, J., Loskog, A., Mustjoki, S., Porkka, K., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.03.067 · Cited by 122
Self-citationMcComb, S., Aguadé-Gorgorió, J., Harder, L., Marovca, B., Cario, G., Eckert, C., Schrappe, M., Stanulla, M., von Stackelberg, A., Bourquin, J.-P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2986 · Cited by 115
Noonan, A. M., Bunch, K. P., Chen, J., Herrmann, M. A., Lee, J., Kohn, E. C., O'Sullivan, C. C., Jordan, E., Houston, N., Takebe, N., et al. (2016) · Cancer · doi:10.1002/cncr.29783 · Cited by 104
Antagonism of IAPs Enhances CAR T-cell Efficacy
Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0428 · Cited by 99
Leitner, J. M., Kuschei, W. M., Grabmeier‐Pfistershammer, K., Woitek, R., Kriehuber, E., Majdic, O., Zlabinger, G. J., Pickl, W. F., & Steinberger, P. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.020 · Cited by 91
Self-citationGlobal survey of the immunomodulatory potential of common drugs
Vladimer, G. I., Snijder, B., Krall, N., Bigenzahn, J. W., Huber, K. V. M., Lardeau, C.-H., Sanjiv, K., Ringler, A., Berglund, U. W., Sabler, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2360 · Cited by 87
Kim, D.-S., Dastidar, H., Zhang, C., Zemp, F. J., Lau, K., Ernst, M., Rakic, A., Sikdar, S., Rajwani, J., Naumenko, V., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00324-x · Cited by 75
Gentle, I. E., Moelter, I., Lechler, N., Bambach, S. K., Vucikuja, S., Häcker, G. A., & Aichele, P. (2013) · Blood · doi:10.1182/blood-2013-01-479543 · Cited by 47
Pölönen, P., Mehtonen, J., Lin, J., Liuksiala, T., Häyrynen, S., Teppo, S., Mäkinen, A., Kumar, A., Malani, D., Pohjolainen, V., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2970 · Cited by 43
Self-citationData-driven characterization of molecular phenotypes across heterogeneous sample collections
Mehtonen, J., Pölönen, P., Häyrynen, S., Dufva, O., Lin, J., Liuksiala, T., Granberg, K. J., Lohi, O., Hautamäki, V., Nykter, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz281 · Cited by 22
Self-citationBeug, S. T., Beauregard, C. E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D. E., Mohan, A. A., Earl, N., Lun, X. Q., et al. (2018) · Nature Communications · doi:10.1038/ncomms16231 · Cited by 11
Impaired tumor death receptor signaling drives resistance to CAR T cell therapyPreprint
Singh, N., Shestova, O. E., Ravikumar, P., Hayer, K. E., Hong, S. J., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/627562 · Cited by 1
Cited by
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
“Moreover, SMAC mimetics has also been suggested to enhance the efficacy of CAR-T cells in the treatment of acute lymphoblastic leukemia in term of mechanism that death receptor signaling is a key mediator of CAR-T cells cytotoxicity.(427) Vaccinia virus (VACV) is a novel type of immunooncolytic therapy based on the me…”
BackgroundRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Larson, R. C., Kann, M. C., Bailey, S. R., Haradhvala, N. J., Llopis, P. M., Bouffard, A. A., Scarfó, I., Leick, M. B., Grauwet, K., Berger, T. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04585-5 · Cited by 352
Metadata
- Authors
- Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., Ellonen, P., Steinberger, P., Kankainen, M., Aittokallio, T., Keränen, M. A. I., Korhonen, M., & Mustjoki, S.
- Affiliations
- University of Helsinki (FI)
- Finnish Red Cross (FI)
- Medical University of Vienna (AT)
- University of Eastern Finland (FI)
- Corresponding author
- Keränen, Mikko A. I.
- Korhonen, Matti
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-02-27
- Volume
- 135
- Issue
- 9
- Pages
- 597-609
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC7098811
- OpenAlex
- W2997152681
- Cited by
- 224
- References
- 66
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 41 · 2023: 32 · 2022: 54 · 2021: 30 · 2020: 21
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Aaltodoc (Aalto University) (submittedVersion, cc-by)
- UEF eRepo (University of Eastern Finland) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Pfizer
- Helsingin Yliopisto
- Finska Läkaresällskapet
- Incyte
- Biomedicum Helsinki-säätiö
- Orionin Tutkimussäätiö
- Syöpäsäätiö
- Helsinki Institute of Life Science, Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, CAR T cell cytotoxicity, CRISPR-Cas9 loss-of-function screen, tyrosine kinase inhibitors, IAP antagonists, death receptor signaling, FADD, DR5, RIPK1, apoptosis, B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, CD19 CAR T cells, cancer immunotherapy
- MeSH terms
- Receptors, Chimeric Antigen, Cytotoxicity Tests, Immunologic, Cytotoxicity, Immunologic, Drug Screening Assays, Antitumor, Humans, Lymphocyte Activation, T-Lymphocytes, Cytotoxic, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Drug Resistance, Neoplasm, Cell Line, Tumor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.